{
    "nctId": "NCT00397501",
    "briefTitle": "BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain",
    "officialTitle": "A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients",
    "overallStatus": "WITHDRAWN",
    "conditions": "Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects, Drug/Agent Toxicity by Tissue/Organ, Psychosocial Effects of Cancer and Its Treatment",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Overall survival exceeding 5 months in patients with Human Epidermal growth factor Receptor 2(HER2)-negative disease",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer metastatic to the central nervous system (as documented by brain biopsy, cytology \\[analysis from cerebrospinal fluid\\]) OR radiographic evidence of brain metastasis with a diagnosis of systemic breast cancer\n* Patients must have stable or no systemic disease as determined by a CT scan of the chest, abdomen, and pelvis\n* HER2-positive or -negative disease by fluorescent in situ hybridization (FISH) or immunohistochemistry\n* Patients with HER2-positive disease and signs of intracranial herniation and/or spinal block may first undergo intraarterial chemotherapy off study (with carboplatin, methotrexate, and trastuzumab \\[Herceptin\u00ae\\] by the same routes used on study) until radiographically shown to be safe to undergo blood brain barrier disruption, at which point they may be enrolled in the study\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%\n* Life expectancy \\> 6 weeks\n* Hematocrit \u2265 25%\n* WBC \u2265 2,500/mm\u00b3\n* Absolute neutrophil count \u2265 1,200/mm\u00b3\n* Platelet count \u2265100,000/mm\u00b3\n* Creatinine clearance \u2265 50 mL/min (eligible for full-dose methotrexate) (30-49 mL/min allowed for patients receiving reduced-dose methotrexate)\n* Bilirubin \u2264 2.0 times upper limit of normal\n* LVEF normal by echocardiogram or MUGA\n* Adequate pulmonary and cardiac function to tolerate general anesthesia as determined by physical examination and history\n* No New York Heart Association class III-IV heart disease\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No known allergy to trastuzumab (HER2-positive patients), carboplatin, methotrexate, or sodium thiosulfate\n* No hepatitis B or C positivity\n* No uncontrolled intercurrent illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection (e.g., HIV)\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness or social situations that would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior surgery or biopsy allowed\n* Prior chemotherapy and radiation therapy for metastatic breast cancer allowed\n* No radiation or cytotoxic chemotherapy within the past 4 weeks (except trastuzumab or hormone therapy that has been part of the patient's ongoing treatment \\[e.g., aromatase inhibitors for estrogen receptor positive patients\\])\n* No noncytotoxic regimens (e.g., targeted oral agents) within the past 2 weeks\n* No investigational agents within the past 4 weeks\n* No other concurrent anticancer agents or therapies",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}